Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy. Electronic address: g.genestreti@ausl.bologna.it.
Giovenzio
G
Genestreti
Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.
Dario
D
de Biase
Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy.
Monica
M
Di Battista
Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy.
Giovanna
G
Cavallo
Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy.
Roberta
R
Degli Esposti
Department of Medicine (DIMES)-Molecular Diagnostic Unit, AUSL di Bologna, University of Bologna School of Medicine, Bologna, Italy.
Michela
M
Visani
Department of Medicine (DIMES)-Molecular Diagnostic Unit, AUSL di Bologna, University of Bologna School of Medicine, Bologna, Italy.
Giorgia
G
Acquaviva
Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.
Thomas
T
Brand
Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.
Annalisa
A
Pession
Department of Medicine (DIMES)-Molecular Diagnostic Unit, AUSL di Bologna, University of Bologna School of Medicine, Bologna, Italy.
Giovanni
G
Tallini
Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy.
Alba A
AA
Brandes
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000368:Aged; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis*; D004417:Dyspnea / Q000175:diagnosis* / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D005091:Exons / Q000235:genetics; D000077156:Gefitinib; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009154:Mutation / Q000235:genetics; D010996:Pleural Effusion / Q000175:diagnosis* / Q000209:etiology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib
EGFR; NSCLC; Next generation sequencing; Tyrosine kinase inhibitors; Uncommon mutation